Non-profit drug research and development: the case study of Genethon
Non-profit drug research and development (R&D) has the potential to deliver innovative treatments at affordable prices. Using the case study methodology, we discuss some ethical and economic issues, including the possible impact of non-profit companies on innovation efforts from for-profit firms...
Main Authors: | Szymon Jarosławski, Mondher Toumi |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-01-01
|
Series: | Journal of Market Access & Health Policy |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/20016689.2018.1545514 |
Similar Items
-
Quantifying the persisting orphan-drug shortage public health crisis in the United States
by: Szymon Jarosławski, et al.
Published: (2017-01-01) -
Innovation Options and Profitability of Pharmaceutical Brand Manufacturers
by: Norman Hendrik Riedel, et al.
Published: (2022-10-01) -
A comparative study of orphan drug prices in Europe
by: Katherine Eve Young, et al.
Published: (2017-01-01) -
Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
by: Szymon Jarosławski, et al.
Published: (2018-01-01) -
Determinants of orphan drugs prices in France: a regression analysis
by: Daria Korchagina, et al.
Published: (2017-04-01)